Journal
GENES
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/genes11070722
Keywords
trypanosomatids; neglected tropical diseases; Leishmania; Trypanosoma cruzi; Trypanosoma brucei; drug discovery; in vitro models; in vivo models; genomics; drug resistance
Categories
Funding
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2017-04480]
- Canada foundation for Innovation [37324]
- Fonds de Recherche du Quebec-Nature et Technologies (FRQNT) scholarship program
Ask authors/readers for more resources
Leishmaniasis (Leishmaniaspecies), sleeping sickness (Trypanosoma brucei), and Chagas disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by trypanosomatid parasites. At present, drugs for treating trypanosomatid diseases are far from ideal due to host toxicity, elevated cost, limited access, and increasing rates of drug resistance. Technological advances in parasitology, chemistry, and genomics have unlocked new possibilities for novel drug concepts and compound screening technologies that were previously inaccessible. In this perspective, we discuss current models used in drug-discovery cascades targeting trypanosomatids (from in vitro to in vivo approaches), their use and limitations in a biological context, as well as different examples of recently discovered lead compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available